Literature DB >> 6633162

Comparison in animal models of 18F-spiroperidol and 18F-haloperidol: potential agents for imaging the dopamine receptor.

M J Welch, M R Kilbourn, C J Mathias, M A Mintun, M E Raichle.   

Abstract

Fluorine-18-labeled haloperidol and spiroperidol have been prepared by an exchange reaction using the corresponding non-labeled compound or the nitro analog. Studies in rats have shown that the distribution of labeled spiroperidol has a high striatum to cerebellum ratio which is not observed with haloperidol. A ratio of 10.66 +/- 1.6 is obtained two hours after administration of the 18F-spiroperidol. When 18F-spiroperidol was administered to a baboon and tomographic images obtained, the dopamine receptor rich areas were clearly visualized two hours after administration.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6633162     DOI: 10.1016/0024-3205(83)90725-7

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

Review 1.  Tracers for metabolic imaging of brain and heart. Radiochemistry and radiopharmacology.

Authors:  G Stöcklin
Journal:  Eur J Nucl Med       Date:  1992

2.  PET measurement of D2 and S2 receptor binding of 3-N-[( 2'-18F]fluoroethyl)spiperone in baboon brain.

Authors:  H H Coenen; K Wienhard; G Stöcklin; P Laufer; I Hebold; G Pawlik; W D Heiss
Journal:  Eur J Nucl Med       Date:  1988

3.  Characteristics of specific in vivo labeling of neuroleptic binding sites with 3-N-[11C]methylspiperone.

Authors:  K Yanai; T Ido; K Ishiwata; J Hatazawa; S Watanuki; T Takahashi; A Ujiie; M Ito; T Matsuzawa
Journal:  Eur J Nucl Med       Date:  1986

4.  Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography.

Authors:  L Farde; E Ehrin; L Eriksson; T Greitz; H Hall; C G Hedström; J E Litton; G Sedvall
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

5.  Evaluation of 75Br-labelled butyrophenone neuroleptics for imaging cerebral dopaminergic receptor areas using positron emission tomography.

Authors:  S M Moerlein; P Laufer; G Stöcklin; G Pawlik; K Wienhard; W D Heiss
Journal:  Eur J Nucl Med       Date:  1986

Review 6.  PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging.

Authors:  John A Katzenellenbogen
Journal:  Cancers (Basel)       Date:  2020-07-23       Impact factor: 6.639

Review 7.  The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[18F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review.

Authors:  John A Katzenellenbogen
Journal:  Nucl Med Biol       Date:  2020-02-22       Impact factor: 2.408

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.